Literature DB >> 18092155

Disease progression, drug action and Parkinson's disease: why time cannot be ignored.

Nick Holford1, John G Nutt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18092155      PMCID： PMC3390311          DOI： 10.1007/s00228-007-0427-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  25 in total

Review 1.  More efficient clinical trials through use of scientific model-based statistical tests.

Authors:  E Niclas Jonsson; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

2.  Dopamine turnover and glutathione oxidation: implications for Parkinson disease.

Authors:  M B Spina; G Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 3.  Considerations in the management of parkinsonism.

Authors:  S Fahn; D B Calne
Journal:  Neurology       Date:  1978-01       Impact factor: 9.910

4.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz; K Jellinger; F Seitelberger
Journal:  J Neurol Sci       Date:  1973-12       Impact factor: 3.181

5.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

6.  Aromatic amino acids and modification of parkinsonism.

Authors:  G C Cotzias; M H Van Woert; L M Schiffer
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

Review 7.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

8.  Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  Pharm Res       Date:  2007-02-17       Impact factor: 4.200

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet.

Authors:  M V Nelson; R C Berchou; P A Lewitt; D Kareti; N Kesaree; P Schlick; M P Galloway
Journal:  Clin Neuropharmacol       Date:  1989-04       Impact factor: 1.592
View more
  8 in total

1.  Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.

Authors:  Thuy C Vu; John G Nutt; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

2.  Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.

Authors:  Chuanpu Hu; Philippe O Szapary; Newman Yeilding; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-02-13       Impact factor: 2.745

3.  An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.

Authors:  Florence Véronneau-Veilleux; Philippe Robaey; Mauro Ursino; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-21       Impact factor: 2.745

Review 4.  Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.

Authors:  Teun M Post; Serge C L M Cremers; Thomas Kerbusch; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

5.  Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study.

Authors:  M Encarna Micó-Amigo; Idsart Kingma; Sebastian Heinzel; Sietse M Rispens; Tanja Heger; Susanne Nussbaum; Rob C van Lummel; Daniela Berg; Walter Maetzler; Jaap H van Dieën
Journal:  Front Hum Neurosci       Date:  2019-02-19       Impact factor: 3.169

6.  A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.

Authors:  Vignayanandam Ravindernath-Jayashree Muddapu; Karthik Vijayakumar; Keerthiga Ramakrishnan; V Srinivasa Chakravarthy
Journal:  Front Neurosci       Date:  2022-04-19       Impact factor: 5.152

7.  Toward Improved Treatment and Empowerment of Individuals With Parkinson Disease: Design and Evaluation of an Internet of Things System.

Authors:  Liran Karni; Ilir Jusufi; Dag Nyholm; Gunnar Oskar Klein; Mevludin Memedi
Journal:  JMIR Form Res       Date:  2022-06-09

8.  Baseline predictors of progression of Parkinson's disease in a sample of Egyptian patients: clinical and biochemical.

Authors:  Asmaa Helmy; Eman Hamid; Mohamed Salama; Ahmed Gaber; Mahmoud El-Belkimy; Ali Shalash
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2022-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.